Xbrane Biopharma AB (FRA:7XB0) Cyclically Adjusted Revenue per Share: €6.20 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7XB0 Xbrane Biopharma AB FRA:7XB0
71 GF Score
Price €0.77
GF Value €0.49
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB Cyclically Adjusted Revenue per Share?

Xbrane Biopharma AB FRA:7XB0 -1.28% 71 Cyclically Adjusted Revenue per Share is €6.20 as of Jun. 2026. GuruFocus rates FRA:7XB0 with a GF Score™ of 71/100 and a GF Value™ of €0.49. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Xbrane Biopharma AB's adjusted revenue per share for the three months ended in Jun. 2026 was €0.207. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €6.20 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Xbrane Biopharma AB's average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-27), Xbrane Biopharma AB's current stock price is €0.772. Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €6.20. Xbrane Biopharma AB's Cyclically Adjusted PS Ratio of today is 0.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xbrane Biopharma AB was 0.49. The lowest was 0.08. And the median was 0.28.


Xbrane Biopharma AB  (FRA:7XB0) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xbrane Biopharma AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.772/6.20
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xbrane Biopharma AB was 0.49. The lowest was 0.08. And the median was 0.28.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Xbrane Biopharma AB Cyclically Adjusted Revenue per Share Related Terms


Xbrane Biopharma AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB Cyclically Adjusted Revenue per Share Chart

Xbrane Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.99 6.28

Xbrane Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.11 3.59 6.28 5.46 6.20

FRA:7XB0 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Xbrane Biopharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Cyclically Adjusted PS Ratio falls into.


FRA:7XB0
71GF Score
Xbrane Biopharma AB FRA:7XB0
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xbrane Biopharma AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xbrane Biopharma AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.207/134.6100*134.6100
=0.207

Current CPI (Jun. 2026) = 134.6100.

Xbrane Biopharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 2.025 102.022 2.672
201706 1.219 102.752 1.597
201709 0.000 103.279 0.000
201712 2.338 103.793 3.032
201803 1.977 103.962 2.560
201806 1.002 104.875 1.286
201809 0.459 105.679 0.585
201812 20.121 105.912 25.573
201903 0.000 105.886 0.000
201906 0.000 106.742 0.000
201909 0.000 107.214 0.000
201912 0.052 107.766 0.065
202003 0.000 106.563 0.000
202006 0.000 107.498 0.000
202009 0.000 107.635 0.000
202012 0.472 108.296 0.587
202103 0.160 108.360 0.199
202106 0.161 108.928 0.199
202109 0.129 110.338 0.157
202112 0.169 112.486 0.202
202203 0.392 114.825 0.460
202206 1.002 118.384 1.139
202209 0.736 122.296 0.810
202212 0.831 126.365 0.885
202303 2.839 127.042 3.008
202306 2.198 129.407 2.286
202309 2.413 130.224 2.494
202312 2.844 131.912 2.902
202403 0.102 132.205 0.104
202406 0.376 132.716 0.381
202409 0.116 132.304 0.118
202412 0.004 132.987 0.004
202503 0.694 132.825 0.703
202506 0.002 133.699 0.002
202509 0.045 133.480 0.045
202512 0.002 133.390 0.002
202603 0.078 133.560 0.079
202606 0.207 134.610 0.207

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €6.20 mean?
Xbrane Biopharma AB (FRA:7XB0) has a Cyclically Adjusted Revenue per Share of €6.20 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors.
Is Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share too high?
Xbrane Biopharma AB's current Cyclically Adjusted Revenue per Share is €6.20. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share of €6.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current Cyclically Adjusted Revenue per Share is €6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Xbrane Biopharma AB (FRA:7XB0) has a current Cyclically Adjusted Revenue per Share of €6.20. The stock's GF Value™ is €0.49, compared to a current price of €0.77 — trading 57.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €6.20. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Xbrane Biopharma AB (FRA:7XB0), the current Cyclically Adjusted Revenue per Share is €6.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (FRA:7XB0) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of €0.77 is trading 57.6% above its estimated GF Value™ of €0.49.

Key valuation signals for FRA:7XB0:

  • Cyclically Adjusted Revenue per Share: €6.20
  • GF Value™: €0.49 vs. price of €0.77 (57.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:7XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xbrane Biopharma AB Business Description

Other Exchanges XBRANE:Sweden
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score

Get the complete analysis for FRA:7XB0

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€0.49
GF Value